PharmGen Science, Inc. (004720.KS) Stock
PharmGen Science, Inc.

Company profile
PharmGen Science reported revenue of 173.07 billion KRW for fiscal year 2025, up 1.0% from fiscal year 2024. South Korea was its largest region in fiscal year 2024, with 100% of revenue. Our analysis of its filings shows revenue growing from 166.78 billion KRW in fiscal year 2023 to 173.07 billion KRW in fiscal year 2025, 1.9% a year on average. PharmGen Science reports about 226 full-time employees.
What stands out
- It reported a net loss of 116.64 billion KRW in fiscal year 2025, after a profit of 2.79 billion KRW in fiscal year 2024.
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
About PharmGen Science, Inc.
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1966 and is headquartered in Hwaseong-si, South Korea.
Largest shareholders
- Eui-Sang Han11.28 %11.28%
- HD Investment Association3.96%
- Hyun-sook Kim3.168 %3.17%
- Jae-Man Yoo2.52 %2.52%
- Dae-hee Han2.173 %2.17%
Share of the company, as of May 19, 2026
Leadership
- Hee-Deok Park — CEO & Director, 58
- Hye-Youn Kim — Chief Executive Officer
How much revenue does PharmGen Science make?
PharmGen Science reported 173.07 billion KRW in revenue for fiscal year 2025, up 1.0% from 171.29 billion KRW in fiscal year 2024.
Where does PharmGen Science make most of its revenue?
South Korea: 100% of revenue by region in fiscal year 2024, followed by Overseas (under 1%).
What companies are similar to PharmGen Science?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Withus Pharmaceutical Co.,LTD. (330350.KQ), Sinil Pharmaceutical Co., Ltd. (012790.KQ), Daehan Nupharm Co.,Ltd. (054670.KQ), Ctcbio Inc. (060590.KQ).
Has PharmGen Science made a profit in recent years?
Net income by fiscal year: FY2021, 32.47 billion KRW; FY2022, 70.06 billion KRW; FY2023, 6.09 billion KRW; FY2024, 2.79 billion KRW; FY2025, a loss of 116.64 billion KRW. It reported a net loss in 1 of these 5 years.
How has PharmGen Science's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 109.87 billion KRW; FY2022, 150.93 billion KRW; FY2023, 166.78 billion KRW; FY2024, 171.29 billion KRW; FY2025, 173.07 billion KRW.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “PharmGen Science, Inc. (004720.KS)”, data as of May 19, 2026, https://dataporium.tech/stocks/004720.KS